Show simple item record

dc.contributorFen Edebiyat Fakültesi / Faculty of Letters and Sciences Moleküler Biyoloji ve Genetik / Molecular Biology and Geneticstr_TR
dc.contributor.authorArısan, Serdar
dc.contributor.authorÇaşkurlu, Turhan
dc.contributor.authorGüney, Soner
dc.contributor.authorSönmez, Nurettin Cem
dc.contributor.authorKeleş, Bayram
dc.contributor.authorArısan, Elif Damla
dc.contributor.authorErgenekon, Erbil
dc.date.accessioned2019-02-07T13:40:16Z
dc.date.available2019-02-07T13:40:16Z
dc.date.issued2005-09
dc.identifier.issn0301-1623
dc.identifier.other1573-2584
dc.identifier.urihttps://doi.org/10.1007/s11255-005-0919-4
dc.identifier.urihttps://hdl.handle.net/11413/4491
dc.description.abstractObjective: The clinical course of transitional cell carcinoma is highly variable. The determination of sensitive prognostic factors for transitional cell carcinoma is very important. Therefore e-cadherin and p53 immunohistochemical activity can be used with other prognostic factors. Methods: The study comprised with 61 (4 women and 57 men) selected patients who had transitional cell carcinoma. Paraffin embedded tissue sections were investigated immunohistochemically for e-cadherin normal staining and p53 over expression. Results: It is seen that when grade and stages of illness increased normal staining of e-cadherin decreased and p53 over expressed. Abnormal e-cadherin was significantly associated with disease recurrence (P < 0.001), disease progression (P < 0.001) and bladder specific survival. p53 differentiation was not significant for disease recurrence (P > 0.05) inverse to prognosis of illness. Transurethral resectomy and BCG treatments were not effected e-cadherin and p53 activity within the groups statistically. Conclusion: Significant differences can be helpful to investigate patients more detailed pathologically. These expression rates in different type of transitional cell carcinoma patients may represent a biologically more aggressive cancer, requiring early definitive therapy. This hypothesis should be evaluated in larger studies and prospective clinical trials.tr_TR
dc.language.isoen_UStr_TR
dc.publisherKluwer Academic Publisherstr_TR
dc.relationInternational Urology and Nephrologytr_TR
dc.subjectE-cadherinstr_TR
dc.subjectImmunohistochemistrytr_TR
dc.subjectp53tr_TR
dc.subjectPrognosistr_TR
dc.subjectTCCtr_TR
dc.subjectTumor markerstr_TR
dc.titleThe prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patientstr_TR
dc.typeArticletr_TR
dc.contributor.authorID29912tr_TR
dc.contributor.authorID216542tr_TR
dc.contributor.authorID113920tr_TR


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record